Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Comment by esiforon Feb 17, 2022 12:13am
85 Views
Post# 34436760

RE:Options, RSU and Phantom Shares

RE:Options, RSU and Phantom SharesThat is great analysis. Another contributing factor for general sluggish reception of retail investors is that due to its small market cap, analytics sites such as simplywall.st don't have any human being eye over the analysis of the pricing and the automated quantative analytics algorithms pick up the one time COVID revenue injections as a decline in revenue and put the fair market value (FMV) as a much smaller value that a detailed analysis would suggest. Once one or two more quarters pass and the revenue growth pattern emerges again, they will categorize the stock back under "under valued" and a lot of stock screening searchers will start including it.

Combined with incentives of the mangement, I think this is creating a depressed price that will eventually jump in a big shot upward of 30~70% in.a short period where a lot of investors will want to buy into an undervalued stock once it starts showing upward momentum, increasing the price even further.

I observed this in late 2019 and early 2020 right before the pandemic hit. It went from $5 to $10 in a short time span. The only consideration is where bag holders such as myself will decide to cash out creating an upward resistance line. For now, the latest glassdoor review suggests that management is taking the situation seriously and making significant changes in operational efficiency which will reward the shareholders.

<< Previous
Bullboard Posts
Next >>